Home/Pipeline/Next-generation mRNA Vaccines

Next-generation mRNA Vaccines

Infectious Diseases

Phase 1Active

Key Facts

Indication

Infectious Diseases

Phase

Phase 1

Status

Active

Company

BioNTech

About BioNTech

BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases Immunotherapy

Other Infectious Diseases Drugs

Drug	Company	Phase	Status
Genetic Molecular Tests	Eurobio Scientific	Commercial	Commercial
LEAPS Technology	CEL-SCI	Pre-clinical	Early Development
Platform Vaccine Applications	Chimeron Bio	Discovery	Research